PriceTargets.com logo

Repligen - RGEN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $173.85
  • Forecasted Upside: 4.88%
  • Number of Analysts: 15
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$165.76 As of 12/4/2025 05:00 PM ET
▼ -0.76 (-0.46%)

This chart shows the closing price for RGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Repligen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGEN

Analyst Price Target is $173.85
▲ +4.88% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is $173.85, with a high forecast of $205.00 and a low forecast of $150.00. The average price target represents a 4.88% upside from the last price of $165.76.

This chart shows the closing price for RGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 polled investment analysts is to moderate buy stock in Repligen. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/25/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/19/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/13/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
10/29/2025Canaccord Genuity GroupBoost TargetHold ➝ Hold$150.00 ➝ $165.00
10/29/2025BarclaysBoost TargetOverweight ➝ Overweight$160.00 ➝ $175.00
10/28/2025Jefferies Financial GroupSet TargetHold ➝ Hold$160.00
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
10/7/2025Evercore ISIBoost TargetOutperform ➝ Outperform$155.00 ➝ $175.00
10/2/2025BarclaysBoost TargetOverweight ➝ Overweight$150.00 ➝ $160.00
10/1/2025HSBCInitiated CoverageBuy$150.00
10/1/2025Hsbc Global ResUpgradeStrong-Buy
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/22/2025Evercore ISIUpgradeIn-Line ➝ Outperform$130.00 ➝ $155.00
9/12/2025Jefferies Financial GroupLower TargetHold ➝ Hold$145.00 ➝ $135.00
9/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$180.00
9/2/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$205.00
7/30/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$193.00 ➝ $204.00
7/30/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$180.00 ➝ $175.00
7/22/2025StephensUpgradeOverweight$160.00
7/8/2025Evercore ISILower TargetIn-Line ➝ In-Line$140.00 ➝ $130.00
6/24/2025BarclaysInitiated CoverageOverweight$150.00
5/5/2025HC WainwrightReiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
4/30/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$202.00 ➝ $189.00
4/29/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$200.00 ➝ $190.00
4/29/2025Wolfe ResearchUpgradePeer Perform ➝ Outperform$160.00
4/16/2025Canaccord Genuity GroupLower TargetHold ➝ Hold$170.00 ➝ $150.00
3/18/2025Evercore ISIInitiated CoverageIn-Line$155.00
2/21/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$203.00 ➝ $205.00
2/21/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$190.00 ➝ $200.00
2/21/2025Canaccord Genuity GroupBoost TargetHold ➝ Hold$165.00 ➝ $170.00
2/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
2/10/2025TD CowenInitiated CoverageBuy$200.00
1/23/2025HC WainwrightLower TargetBuy ➝ Buy$240.00 ➝ $180.00
12/17/2024Canaccord Genuity GroupInitiated CoverageHold$165.00
12/17/2024Canaccord Genuity GroupInitiated CoverageHold$165.00
11/14/2024Wolfe ResearchInitiated CoveragePeer Perform
9/26/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$205.00 ➝ $205.00
8/27/2024Wells Fargo & CompanyInitiated CoverageOverweight$180.00
8/5/2024BenchmarkReiterated RatingHold
7/31/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$190.00 ➝ $200.00
7/31/2024UBS GroupLower TargetBuy ➝ Buy$205.00 ➝ $185.00
7/31/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$190.00 ➝ $190.00
7/30/2024StephensReiterated RatingOverweight ➝ Overweight$170.00 ➝ $170.00
6/26/2024Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$180.00 ➝ $155.00
6/18/2024GuggenheimInitiated CoverageNeutral
5/2/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$230.00 ➝ $200.00
2/22/2024Stifel NicolausBoost TargetBuy ➝ Buy$165.00 ➝ $207.00
2/15/2024KeyCorpBoost TargetOverweight ➝ Overweight$210.00 ➝ $220.00
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$170.00 ➝ $210.00
12/4/2023BenchmarkDowngradeBuy ➝ Hold
11/2/2023UBS GroupLower TargetBuy ➝ Buy$210.00 ➝ $170.00
11/1/2023Stifel NicolausLower TargetBuy ➝ Buy$200.00 ➝ $165.00
11/1/2023Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$207.00 ➝ $200.00
11/1/2023KeyCorpLower TargetOverweight ➝ Overweight$240.00 ➝ $210.00
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$200.00 ➝ $180.00
9/6/2023Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$191.00
8/3/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$157.00 ➝ $195.00
8/3/2023Craig HallumLower TargetBuy ➝ Buy$207.00 ➝ $200.00
8/3/2023StephensBoost TargetOverweight ➝ Overweight$180.00 ➝ $200.00
7/20/2023Wells Fargo & CompanyInitiated CoverageOverweight$185.00
7/6/2023Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform
6/28/2023Stifel NicolausLower Target$210.00 ➝ $200.00
5/3/2023Deutsche Bank AktiengesellschaftLower Target$180.00 ➝ $165.00
5/3/2023Royal Bank Of CanadaLower Target$170.00 ➝ $157.00
5/3/2023Craig HallumLower Target$220.00 ➝ $207.00
5/3/2023BenchmarkLower Target$230.00 ➝ $210.00
5/3/2023Stifel NicolausLower Target$225.00 ➝ $210.00
3/27/2023BenchmarkInitiated CoverageBuy$230.00
2/23/2023Craig HallumLower Target$251.00 ➝ $220.00
2/23/2023KeyCorpLower TargetOverweight$260.00 ➝ $240.00
1/6/2023Leerink PartnersLower TargetOutperform$230.00 ➝ $200.00
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$180.00
12/6/2022Royal Bank Of CanadaInitiated CoverageSector Perform$190.00
11/2/2022William BlairReiterated RatingOutperform
11/2/2022Craig HallumLower Target$274.00 ➝ $251.00
8/3/2022Leerink PartnersBoost TargetOutperform$220.00 ➝ $250.00
8/3/2022StephensBoost TargetOverweight$220.00 ➝ $275.00
8/3/2022KeyCorpBoost TargetOverweight$245.00 ➝ $260.00
7/20/2022UBS GroupInitiated CoverageBuy$213.00
4/28/2022Craig HallumLower Target$286.00 ➝ $274.00
2/18/2022Leerink PartnersLower TargetOutperform$275.00 ➝ $250.00
12/20/2021Leerink PartnersReiterated RatingBuy
10/29/2021Leerink PartnersBoost TargetOutperform$260.00 ➝ $325.00
10/14/2021Exane BNP ParibasInitiated CoverageOutperform$330.00
10/14/2021BNP ParibasInitiated CoverageOutperform$330.00
9/27/2021Craig HallumBoost TargetBuy$258.00 ➝ $368.00
9/17/2021KeyCorpBoost TargetOverweight$255.00 ➝ $335.00
8/20/2021StephensBoost TargetOverweight$255.00 ➝ $290.00
7/28/2021Craig HallumBoost TargetBuy$251.00 ➝ $258.00
5/5/2021HC WainwrightBoost TargetBuy$225.00 ➝ $240.00
4/19/2021HC WainwrightReiterated RatingBuy$168.00 ➝ $225.00
4/12/2021HC WainwrightBoost TargetBuy$168.00 ➝ $225.00
2/25/2021Craig HallumBoost TargetBuy$245.00 ➝ $251.00
2/25/2021Leerink PartnersBoost TargetOutperform$220.00 ➝ $250.00
1/20/2021Craig HallumBoost TargetBuy$229.00 ➝ $245.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.25 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 43 very positive mentions
  • 25 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 26 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 16 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 27 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
8/6/2025
  • 40 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 26 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 27 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 41 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 41 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Repligen logo
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $165.76
Low: $161.67
High: $167.67

50 Day Range

MA: $153.07
Low: $124.09
High: $171.76

52 Week Range

Now: $165.76
Low: $102.96
High: $182.52

Volume

599,190 shs

Average Volume

796,665 shs

Market Capitalization

$9.33 billion

P/E Ratio

8,292.15

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Repligen?

The following Wall Street research analysts have issued stock ratings on Repligen in the last year: Barclays PLC, Canaccord Genuity Group Inc., Evercore ISI, HC Wainwright, Hsbc Global Res, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Royal Bank Of Canada, Stephens, TD Cowen, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for RGEN.

What is the current price target for Repligen?

0 Wall Street analysts have set twelve-month price targets for Repligen in the last year. Their average twelve-month price target is $173.85, suggesting a possible upside of 4.9%. Royal Bank Of Canada has the highest price target set, predicting RGEN will reach $205.00 in the next twelve months. HSBC Holdings plc has the lowest price target set, forecasting a price of $150.00 for Repligen in the next year.
View the latest price targets for RGEN.

What is the current consensus analyst rating for Repligen?

Repligen currently has 1 sell rating, 3 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RGEN.

What other companies compete with Repligen?

Other companies that are similar to Repligen include Bio-Techne, Agilent Technologies, Danaher, Mettler-Toledo International and Thermo Fisher Scientific. Learn More about companies similar to Repligen.

How do I contact Repligen's investor relations team?

Repligen's physical mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company's listed phone number is (781) 250-0111 and its investor relations email address is [email protected]. The official website for Repligen is www.repligen.com. Learn More about contacing Repligen investor relations.